Trial Profile
Improvement of Outcome in Elderly Patients or Patients Not Eligible for High-dose Chemotherapy With Aggressive NHL in First Relapse/Progression by Adding Nivolumab to Gemcitabine, Oxaliplatin Plus Rituximab in Case of B-cell Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 19 Jan 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Gemcitabine; Oxaliplatin; Rituximab
- Indications B-cell lymphoma; Non-Hodgkin's lymphoma; T-cell lymphoma
- Focus Therapeutic Use
- Acronyms NIVEAU
- 12 Dec 2023 Interim results (N=180) presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 09 May 2023 Planned primary completion date changed from 1 Nov 2023 to 1 Nov 2024.
- 09 May 2023 Status changed from recruiting to active, no longer recruiting.